Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2022 Filed Sep 23, 2022 10:36 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,637 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001493152-22-026611 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,637 Underlying: Common Stock, par value $0.01 per share · 16,637 shares Expires 2032-09-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 10:33 UTC |
Laxminarain PrattipatiDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,637 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001493152-22-026610 · ownership.xml · derivative · entry 1 Laxminarain Prattipati · CIK 0001725204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,637 Underlying: Common Stock, par value $0.01 per share · 16,637 shares Expires 2032-09-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:30 UTC |
Vaknin RachelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001493152-22-019940 · ownership.xml · derivative · entry 1 Vaknin Rachel · CIK 0001923217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2032-07-18 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on January 18, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC |
Morag EyalChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002553 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC |
Sharon SimonGeneral Manager, CTO
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002552 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC |
Gadot HarelDirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002551 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.01 per share · 100,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:27 UTC |
Wenderow Tal BaruchDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024680 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:24 UTC |
Stockburger Aileen PtuchaDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024678 · ownership.xml · derivative · entry 1 Stockburger Aileen Ptucha · CIK 0001806682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:22 UTC |
Laxminarain PrattipatiDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024676 · ownership.xml · derivative · entry 1 Laxminarain Prattipati · CIK 0001725204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:15 UTC |
Bornstein YosephDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024672 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:20 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024674 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:12 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024670 · ownership.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:15 UTC |
Gadot HarelDirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001493152-21-002536 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock, par value $0.01 per share · 190,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on February 1, 2022, the options shall vest and shall become exercisable with respect to 50% of the common stock; and (b) on a quarterly basis thereafter over the following year, the option shall equally vest and become exercisable with respect to the remaining 50% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020845 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC |
Laxminarain PrattipatiDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020846 · ownership.xml · derivative · entry 1 Laxminarain Prattipati · CIK 0001725204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC |
Bornstein YosephDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020844 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020843 · ownership.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 19, 2020 Filed Oct 21, 2020 21:22 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 4,881 | $7.94 | $38,734.64 |
DisclosureSEC source: 0001493152-20-019762 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 242,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 4,881 shares of Issuer common stock on October 19, 2020. Accordingly, Reporting Person beneficially owned 242,028 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 12, 2020 Filed Oct 21, 2020 21:25 UTC Amendment |
Bornstein YosephDirector
|
SaleCommon Stock | 20,000 | $7.84 | $156,898.00 |
DisclosureSEC source: 0001493152-20-019763 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 246,909 F1 · date: The original Form 4 filed on October 13, 2020 is amended by this Form 4 amendment to correctly reflect the transaction date in Table 1, Item 2. No other changes have been made to the original Form 4. F2 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 12, 2020. Accordingly, Reporting Person beneficially owned 246,909 shares of Issuer common stock following the reported transactions. F3 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:58 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 5,119 | $7.74 | $39,636.93 |
DisclosureSEC source: 0001493152-20-019036 · ownership.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 266,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 5, 2020. Accordingly, Reporting Person beneficially owned 266,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:58 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 14,881 | $7.74 | $115,213.17 |
DisclosureSEC source: 0001493152-20-019036 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 272,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 5, 2020. Accordingly, Reporting Person beneficially owned 266,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 05, 2020 Filed Oct 13, 2020 21:00 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 20,000 | $7.84 | $156,898.00 |
DisclosureSEC source: 0001493152-20-019358 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 246,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 20,000 shares of Issuer common stock on October 12, 2020. Accordingly, Reporting Person beneficially owned 246,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:30 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 119 | $11.91 | $1,417.44 |
DisclosureSEC source: 0001493152-20-016316 · ownership.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 286,909 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,119 shares of Issuer common stock on August 17, 2020. Accordingly, Reporting Person beneficially owned 286,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:30 UTC |
Bornstein YosephDirector
|
SaleCommon Stock | 15,000 | $10.18 | $152,676.00 |
DisclosureSEC source: 0001493152-20-016316 · ownership.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 287,028 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,119 shares of Issuer common stock on August 17, 2020. Accordingly, Reporting Person beneficially owned 286,909 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| August 14, 2020 Filed Sep 9, 2020 20:45 UTC |
Wenderow Tal BaruchDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,902 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001493152-20-017485 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,902 Underlying: Common Stock, par value $0.01 per share · 4,902 shares Expires 2030-08-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan (the "Plan"): (a) on February 14, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:04 UTC |
Stockburger Aileen PtuchaDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,493 | $0.00 Strike: $6.16 | $0.00 |
DisclosureSEC source: 0001493152-20-013461 · ownership.xml · derivative · entry 1 Stockburger Aileen Ptucha · CIK 0001806682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,493 Underlying: Common Stock, par value $0.01 per share · 6,493 shares Expires 2030-07-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan (the "Plan"): (a) on March 26, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:05 UTC |
Morag EyalChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.16 | $0.00 |
DisclosureSEC source: 0001493152-20-013462 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2030-07-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan (the "Plan"): (a) on December 15, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan and with respect to certain business transactions. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:00 UTC |
Gadot HarelDirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 166,666 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001493152-20-003083 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock, par value $0.01 per share · 166,666 shares Expires 2030-02-25 Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 12:36 UTC |
Gadot HarelDirector · Chairman, President and CEO
|
SaleCommon Stock, par value $0.01 per share | 40,000 | $10.00 | $400,000.00 |
DisclosureSEC source: 0001493152-19-019697 · ownership.xml · nonDerivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By MEDX Ventures Group, LLC Disclosed balance after: 136,847 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in April 2019. F2 · balance_after: Does not include any options to purchase common stock owned by the reporting person. F3 · ownership.nature: Mr. Gadot is the Chief Executive Officer, Company Group Chairman and majority equity owner of MEDX Venture Group and thus may be deemed to share voting and investment power over the shares beneficially owned by this entity. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:21 UTC |
Bornstein YosephDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015942 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:16 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015938 · ownership.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:14 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015936 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:11 UTC |
Laxminarain PrattipatiDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015931 · ownership.xml · derivative · entry 1 Laxminarain Prattipati · CIK 0001725204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:10 UTC |
Waizer Yoav ZviDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015927 · ownership.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:50 UTC |
Laxminarain PrattipatiDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000868 · ownership.xml · derivative · entry 1 Laxminarain Prattipati · CIK 0001725204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:47 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000866 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:44 UTC |
Bornstein YosephDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000864 · ownership.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:44 UTC |
Waizer Yoav ZviDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000863 · ownership.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:43 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000862 · ownership.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 14, 2019 Filed Oct 18, 2019 14:15 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 281,773 | $8.16 | $2,299,267.68 |
DisclosureSEC source: 0001791387-19-000002 · primary_doc.xml · nonDerivative · entry 4 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 14, 2019 Filed Oct 28, 2019 13:32 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 281,773 | $8.16 | $2,299,267.68 |
DisclosureSEC source: 0001791387-19-000004 · primary_doc.xml · nonDerivative · entry 5 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 14, 2019 Filed Oct 28, 2019 13:32 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 1,773 | $6.43 | $11,400.39 |
DisclosureSEC source: 0001791387-19-000004 · primary_doc.xml · nonDerivative · entry 4 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 09, 2019 Filed Oct 18, 2019 14:15 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 2,269 | $2.70 | $6,126.30 |
DisclosureSEC source: 0001791387-19-000002 · primary_doc.xml · nonDerivative · entry 3 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 09, 2019 Filed Oct 18, 2019 14:15 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 14,280 | $2.19 | $31,273.20 |
DisclosureSEC source: 0001791387-19-000002 · primary_doc.xml · nonDerivative · entry 2 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 09, 2019 Filed Oct 28, 2019 13:32 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 1,280 | $2.27 | $2,905.60 |
DisclosureSEC source: 0001791387-19-000004 · primary_doc.xml · nonDerivative · entry 3 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 09, 2019 Filed Oct 28, 2019 13:32 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 14,280 | $2.19 | $31,273.20 |
DisclosureSEC source: 0001791387-19-000004 · primary_doc.xml · nonDerivative · entry 2 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 08, 2019 Filed Oct 18, 2019 14:15 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 2,269 | $2.70 | $6,126.30 |
DisclosureSEC source: 0001791387-19-000002 · primary_doc.xml · nonDerivative · entry 1 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 08, 2019 Filed Oct 28, 2019 13:32 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 2,269 | $2.70 | $6,126.30 |
DisclosureSEC source: 0001791387-19-000004 · primary_doc.xml · nonDerivative · entry 1 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 26, 2018 Filed Oct 18, 2019 13:40 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 37,986 | $1.95 | $74,072.70 |
DisclosureSEC source: 0001791387-19-000001 · primary_doc.xml · nonDerivative · entry 4 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,971 Read SEC document |
| November 21, 2018 Filed Oct 18, 2019 13:40 UTC |
Mona Joseph10% owner
|
SaleMicrobot Medical Common Stock | 6,309 | $2.96 | $18,674.64 |
DisclosureSEC source: 0001791387-19-000001 · primary_doc.xml · nonDerivative · entry 3 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,971 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.